Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Generalized Myasthenia Gravis
NCT06456580Phase 3Active, not recruiting
- Sponsor
- Vor Bio
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of telitacicept in myasthenia gravis (MG), sponsored by Vor Bio. Started Jul 2024; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06456580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456580.